Characterization of Mid-term Post Market Clinical Follow Up of GORE TAG Thoracic Branch Endoprosthesis in Aortic Arch and Descending Aorta Interventions

What this Trial Is About

This observational study collects mid-term post-market clinical follow-up data on the GORE4 TAG4 Thoracic Branch Endoprosthesis, a device used in patients with vascular diseases such as thoracic aortic aneurysm and aortic dissection. The study aims to evaluate questions about the device's efficacy and safety when used according to standard medical practice. Participants in this registry are patients treated with the GORE4 TAG4 Thoracic Branch Endoprosthesis device. Treatment decisions and patient selection are made by physicians based on routine clinical care, without specific requirements imposed by the study sponsor. Patients will have regular follow-up visits as determined by their surgeons and report any device or surgery-related issues during these visits. Throughout the study, participants will undergo assessments during scheduled visits as requested by their surgeon. Researchers will track outcomes such as technical success of device deployment, mortality related to the treated lesion, device migration, stroke, paraplegia, renal function changes, and need for further interventions up to two years after surgery. Additional safety events like bleeding, ischemia, and false lumen status will also be monitored. Participant involvement continues as long as standard care follow-up is maintained, with data collection aligned with routine clinical visits.

Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis